Many Johnson & Johnson ( NYSE:JNJ ) insiders ditched their stock over the past year, which may be of interest to the...
J&J is doubling down on medtech, a typically sleepy sector that has been risky, as it looks to grow after spinning of consumer health segment Kenvue.
NEW BRUNSWICK, N.J., April 16, 2024--In the section titled "Full-Year 2024 Guidance", in the table, row titled "Operational Sales2,5/ Mid-point", the numbers for the April 2024 column should read: $88.7B – $89.1B / $88.9B (instead of: $88.7B – $89.1B / $88.0B).